Genmab A/S (NASDAQ:GMAB) today announced data from its ongoing phase 1/2 EPCORE™ NHL-2 trial investigating epcoritamab, a T-cell engaging bispecific antibody administered subcutaneously, in combination with rituximab-lenalidomide (R2) showed an overall response rate (ORR) of 98 percent and complete metabolic response (CMR) of 87 percent in response evaluable patients (n=104) with relapsed or refractory (R/R) follicular lymphoma (FL). These preliminary results will be presented today during an oral presentation at the 2023 European Hematology Association (EHA) Congress, being held in Frankfurt, Germany and virtually, June 8-11, 2023 (Abstract #S222). Epcoritamab is being co-developed by Genmab and AbbVie (NYSE:ABBV) as part of the companies’ oncology collaboration.
Fear & Greed Index Remains In ‘Fear’ Zone Ahead Of Friday’s Jobs Report
The CNN Money Fear and Greed index remained in the "fear" zone after US stocks recorded a slight decline on Wednesday.
US stocks saw a major surge earlier during the week, with the S&P 500 index recording its biggest two-session rise since 2020.
However, yields rose sharply on Wednesday, which exerted put pressure on the Wall Street for most of the session.
